Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:FBRX NASDAQ:HCWB NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.73-2.8%$1.62$1.03▼$2.41$53.97M-0.3404,221 shs161,615 shsFBRXForte Biosciences$11.05+0.5%$11.12$4.11▼$28.68$136.76M2.6978,061 shs59,219 shsHCWBHCW Biologics$5.35-6.5%$4.45$2.77▼$100.80$12.31M0.74.54 million shs104,458 shsTNYATenaya Therapeutics$1.08-4.4%$0.83$0.36▼$4.01$184.16M3.073.96 million shs2.34 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-2.81%-2.81%+7.45%+1.17%-13.07%FBRXForte Biosciences+0.45%-1.87%+14.98%+10.72%+39.87%HCWBHCW Biologics-6.47%-9.17%+29.54%-12.87%-70.99%TNYATenaya Therapeutics-4.42%0.00%+61.05%+105.05%-59.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals1.895 of 5 stars3.53.00.00.01.10.00.6FBRXForte Biosciences3.4355 of 5 stars3.55.00.00.03.01.70.6HCWBHCW Biologics3.2583 of 5 stars3.55.00.00.03.51.70.0TNYATenaya Therapeutics2.9542 of 5 stars3.51.00.00.02.54.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50160.12% UpsideFBRXForte Biosciences 3.00Buy$68.00515.38% UpsideHCWBHCW Biologics 3.00Buy$35.00554.21% UpsideTNYATenaya Therapeutics 3.00Buy$6.25478.70% UpsideCurrent Analyst Ratings BreakdownLatest HCWB, ATNM, TNYA, and FBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/27/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.008/7/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$7.93 per shareN/AHCWBHCW Biologics$2.57M4.48N/AN/A($0.02) per share-267.50TNYATenaya TherapeuticsN/AN/AN/AN/A$0.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/AFBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)HCWBHCW Biologics-$30.02M-$14.04N/A∞N/A-1,368.55%N/A-40.72%N/ATNYATenaya Therapeutics-$111.13M-$0.96N/AN/AN/AN/A-93.83%-75.66%11/5/2025 (Estimated)Latest HCWB, ATNM, TNYA, and FBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025HCWBHCW Biologics$1.80-$6.79-$8.59-$6.79$7.00 million$0.01 million8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/6/2025Q2 2025TNYATenaya Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25FBRXForte BiosciencesN/A11.7411.74HCWBHCW BiologicsN/A0.110.11TNYATenaya TherapeuticsN/A6.006.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%FBRXForte Biosciences77.63%HCWBHCW Biologics2.96%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%FBRXForte Biosciences5.90%HCWBHCW Biologics42.70%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableHCWBHCW Biologics402.15 million1.23 millionNot OptionableTNYATenaya Therapeutics110162.98 million83.69 millionOptionableHCWB, ATNM, TNYA, and FBRX HeadlinesRecent News About These CompaniesTenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2 at 4:05 PM | globenewswire.comTenaya Therapeutics Reports Interim Data from Largest Pediatric MYBPC3-Associated HCM Study Highlighting Urgent Need for Novel TherapeuticsAugust 31 at 10:31 AM | quiverquant.comQTenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025August 31 at 10:15 AM | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightAugust 29, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)August 29, 2025 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from AnalystsAugust 28, 2025 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from BrokeragesAugust 26, 2025 | americanbankingnews.comFaraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockAugust 20, 2025 | marketbeat.comTenaya Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comWhat is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?August 11, 2025 | marketbeat.comQ3 EPS Estimate for Tenaya Therapeutics Lifted by AnalystAugust 11, 2025 | marketbeat.comWall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to HoldAugust 10, 2025 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at Chardan CapitalAugust 8, 2025 | marketbeat.comTenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 8, 2025 | globenewswire.comTenaya Therapeutics reports Q2 EPS (14c), consensus (19c)August 7, 2025 | msn.comTenaya Therapeutics (TNYA) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comTenaya (TNYA) Q2 Loss Narrows 59%August 7, 2025 | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comEquities Analysts Offer Predictions for TNYA Q1 EarningsAugust 4, 2025 | marketbeat.comLifesci Capital Issues Negative Outlook for TNYA EarningsAugust 4, 2025 | marketbeat.comTenaya Therapeutics stock rises after positive safety reviews for heart gene therapiesJuly 30, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCWB, ATNM, TNYA, and FBRX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.73 -0.05 (-2.81%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$1.72 -0.01 (-0.87%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Forte Biosciences NASDAQ:FBRX$11.05 +0.05 (+0.45%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$10.78 -0.27 (-2.44%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.HCW Biologics NASDAQ:HCWB$5.35 -0.37 (-6.47%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$5.32 -0.03 (-0.56%) As of 09:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Tenaya Therapeutics NASDAQ:TNYA$1.08 -0.05 (-4.42%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.46%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
